Triple-Negative Breast Cancer Drugs are Focus of Partnership Between SRI Biosciences, Stanford Cancer Institute
News
SRI International and Stanford Cancer Institute will collaborate on an innovative new venture to develop investigational drugs to treat triple-negative breast cancer (TNBC). This new research collaboration will look into the potential ... Read more